

## **Concise Review: Prostate Cancer Stem Cells: Current Understandin**

Skvortsov, S.; Skvortsova, I. I.; Tang, D. G.; Dubrovskaya, A.;

Originally published:

June 2018

**Stem Cells 36(2018), 1457-1474**

DOI: <https://doi.org/10.1002/stem.2859>

Perma-Link to Publication Repository of HZDR:

<https://www.hzdr.de/publications/Publ-28833>

Release of the secondary publication  
on the basis of the German Copyright Law § 38 Section 4.

1

**Prostate cancer stem cells: current understanding.**Sergej Skvortsov<sup>1</sup>, Ira, Ida Skvortsova<sup>2, 3</sup>, Dean G Tang<sup>4, 5</sup>, Anna Dubrovskaja<sup>6</sup>

<sup>1</sup>Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Laboratory for Experimental and Translational Research on Radiation Oncology (EXTRO, Lab), Innsbruck, Austria; <sup>2</sup>Dept. of Therapeutic Radiology and Oncology, Innsbruck Medical University, Laboratory for Experimental and Translational Research on Radiation Oncology (EXTRO, Lab), Innsbruck, Austria; <sup>3</sup>Tyrolean Cancer Research Institute, Innsbruck, Austria;

<sup>4</sup>Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;

<sup>5</sup>Cancer Stem Cell Institute, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China;

<sup>6</sup>OncoRay , National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; German Cancer Consortium (DKTK); DKFZ Heidelberg, Germany

Correspondence to:

Anna Dubrovskaja, email: Anna.Dubrovskaja@OncoRay.de

2

## **Abstract**

Prostate cancer (PCa) is heterogeneous harboring phenotypically diverse cancer cell types. PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition and evolution of the cancer genome and by epigenetic mechanisms that result in subclonal cellular differentiation. The process of tumor cell differentiation is initiated from a population of prostate cancer stem cells (PCSCs) that possess many phenotypic and functional properties of normal stem cells. Since the initial reports of PCSCs in 2005, there has been much effort to elucidate their presence and properties. In this review we discuss the current methods for PCSC enrichment and analysis, the hallmarks of PCSC metabolisms and the role of PCSCs in tumor progression.

### **1. Prostate cancer hierarchy, heterogeneity and plasticity**

#### **1.1. Cancer stem cells**

Cellular heterogeneity represents an omnipresent feature of most human tumors. Cancer cell heterogeneity can result, in principle, from both clonal competition and evolution (i.e., selection of the 'fittest' clone) driven by genetic instability inherently high in tumor cells as well as intra-clonal (subclonal) cellular maturation (differentiation) program driven by epigenetic mechanisms (1). The latter process of cell diversification is initiated from a subset of unique cancer cells that possess many phenotypic and functional properties of normal stem cells, hence cancer stem cells (CSCs). In the most strict sense, a single CSC should be able to regenerate a tumor that histo-structurally recapitulates the parent (patient) tumor that consists of all different cancer cell types. No such a CSC has ever been reported in any tumor. In reality, CSCs are operationally defined as cell subpopulations that are enriched in tumor-regenerating and (serial)

3

tumor, propagating activities (2). CSCs should be distinguished from cancer cell, of, origin as the latter refers to the initial normal cell that became tumorigenically transformed (2).

Like most human solid tumors, prostate cancer (PCa) is heterogeneous harboring diverse cancer cell types. PCa cell heterogeneity tends to become accentuated during disease progression and, in particular, upon treatment. This is best evidenced by PCa cells that express AR and PSA – although most untreated primary tumors contain AR<sup>+</sup> and PSA<sup>+</sup> cells as the majority, AR<sup>-</sup> and PSA<sup>-</sup> PCa cells become gradually enriched in high, grade untreated tumor and PSA<sup>-</sup> PCa cells frequently become the predominant cell population in castration, resistant PCa (CRPC) (3). Ever since the initial reports by 3 independent groups (4,6), in 2005, of PCa stem cells (PCSCs), there has been now substantial evidence for the presence and functions of PCSCs, which we shall further elaborate below.

## 1.2. Current methods for PCSC enrichment and analysis

The first proof of principle studies for prospective identification of PCSC exploited different phenotypes to isolate self, renewing and tumorigenic cells from patient derived prostate tumors and cell lines (4,6). These phenotypes included expression of surface markers CD44<sup>+</sup>/α2β1<sup>hi</sup>/CD133<sup>+</sup>, expression of transporter protein ATP, binding cassette sub, family G member 2 (ABCG2) that is involved in the cell detoxification and “side population” phenotype which is defined by Hoechst dye exclusion by tumor cells (4,6).

Since then, a few other markers have been described for human PCSC populations, e.g., CD166 (7), aldehyde dehydrogenase (ALDH) (8), CD44<sup>+</sup>/CD24<sup>-</sup> (9), and C, X, C chemokine receptor type 4 (CXCR,4) (10). PCa cells carrying these markers have capacities to self, renew and to generate the heterogeneous tumor cell populations.

4

Using antibodies to the membrane CSC markers and fluorescence activated cell sorting (FACS) or magnetic cell sorting (MACS), marker positive and marker negative cells can be isolated from cancer cell lines, xenograft tumors and patient-derived specimens, and CSC properties of these cell populations can be analyzed and compared (Table 1).

In addition to the isolation of CSC population based on the marker expression, other strategies exploiting the CSC specific gene reporters are being developed for real-time analysis of CSC behavior at a single-cell level *in vitro* and in animal models. These systems are based on the stable expression of reporter gene (e.g. fluorescent protein) driven by the promoters of CSC, or lineage-specific genes such as NANOG, prostate specific antigen (PSA), Sox2, and OCT4 (11,16) (Table 1).

The methodology exploiting the marker-based CSC isolation and enrichment markedly contributed to the progress in cancer stem cell research, however it is necessary to take into account that the majority of the above-described markers were also identified in the malignant tumors of other origins, such as breast, colorectal, ovarian, lung carcinomas and glioblastoma (17,19). It is also known that these markers are not specifically expressed in malignant tissues, they were also found on the normal embryonic and adult stem cells. Therefore, further investigation of additional reliable and more CSC-specific markers is needed to improve the marker-based CSC harvesting techniques. More specific CSC isolation can markedly contribute to the elucidation of CSC-specific molecular and functional properties.

Since some of CSC populations are described to be treatment-resistant, there is a strategy to enrich CSCs by the repetitive use of chemotherapeutics or radiation therapy (20). PCa cell cultivation in the presence of cytostatic drugs or after radiation exposure led to the development of the acquired treatment resistance and enrichment of

5

1  
2  
3 carcinoma cells positive for CSC markers and having high tumorigenic capacities (20).  
4  
5 Some of the treatment resistant CSC populations are characterized by upregulation of  
6  
7 ABC family members including ABCG2 transporter. This fact provides a background to  
8  
9 use a side population technique for CSC isolation (21). For this, tumor cells either from  
10  
11 cell cultures or from the dissociated xenograft or primary human tumors are stained with  
12  
13 Hoechst 33342 or Rhodamine 123 dyes. Further cell analysis by flow cytometry enables  
14  
15 detecting the cells with increased dye efflux (side population) (6, 22). It is suggested that  
16  
17 CSCs with a high expression of ABC transporters actively release the dye out of the  
18  
19 cells. Unfortunately, this method has a number of limitations. First, Hoechst 33342 and  
20  
21 Rhodamine 123 are toxic for cells. Next, an efficiency of CSC isolation based on side  
22  
23 population might be hampered by low specificity and inconsistency of the existing  
24  
25 staining protocols. Despite the fact that carcinoma cells with acquired therapy resistance  
26  
27 usually demonstrate upregulation of CSC biomarkers, it is important to mention that  
28  
29 treatment-resistant cells do not necessary represent an unified cell population, but rather  
30  
31 a mixture of phenotypically different cell subsets with different properties (23). A number  
32  
33 of studies indicate that therapy might act as a selective pressure on preexisting CSC  
34  
35 populations, but also in some cases might induce tumor cell dedifferentiation (3, 20, 24).  
36  
37  
38  
39  
40  
41

42 CSCs can also be identified and isolated using the differences in sizes between  
43  
44 non-CSCs and CSCs. It was described that CSCs are markedly smaller than more  
45  
46 differentiated cells (25, 26). Recent study of Li et al. showed that a population of small  
47  
48 PC3 PCa cells (<10 Pm) has a tendency of being more tumorigenic as compared to the  
49  
50 large ( $\geq 20$  or 30 Pm) cells (26). Our unpublished studies demonstrated that prostate  
51  
52 tumor cells with upregulation of CD44<sup>+</sup>/CD24<sup>-</sup> markers are smaller in their sizes as  
53  
54 compared with marker negative cells. Further investigation is warranted to clarify the  
55  
56  
57  
58  
59  
60

6

mechanisms controlling cell size in homeostasis and cancer and whether cell size can be effectively used for CSC identification and isolation.

Growing the established cell lines or patient derived tumor cells under serum, free and sphere forming conditions was one of the first methods to enrich CSC population *in vitro*. Most of the cells cultured under these harsh conditions undergo anoikis and die. The survived cell populations are enriched in sphere forming cells, which can sustain their proliferation independent on the cell attachment mechanisms. This assay also allows investigating the cancer cell populations with self, renewal properties if the sphere formation is analyzed in multiple passages, because only self, renewing cells are capable of maintaining their spherogenicity in multiple generations (3, 27). Despite an enrichment of cells expressing CSC markers under sphere forming conditions, it might not necessary correspond to their tumorigenic abilities in xenograft models (28). Kuch et al (2012) suggested that capacities of carcinoma cells to form spheres cannot be used as a reliable surrogate assay to detect the tumor, initiating capacities in animals (28). The report of Matilainen et al. (2012) indicated that  $\alpha 2\beta 1^+$  prostate tumor cells with high clonogenic and sphere forming capacities did not have high tumorigenic abilities in xenograft mice models (29).

In that respect, *in vivo* limiting dilution assay should be performed as a standard technique to analyze the frequency of tumor initiating cells in the cancer cell populations defined by putative CSC markers. For this analysis, the same numbers of marker positive and marker negative cancer cells isolated either from cancer cell lines or from dissociated xenograft or human tumor specimens are injected into immunodeficient mice by orthotopic or ectopic implantation. The cells are injected at the different dilutions: from a few or even single cell to thousands or millions cells, and tumor growth is monitored by

7

1  
2  
3 caliper measurements and tumor bioluminescence for a few months (3, 6, 30). Analysis  
4  
5 of tumor incidence for the different numbers of injected cells enables to estimate the  
6  
7 CSC frequencies in the injected cell populations (2). To validate if putative CSC  
8  
9 populations indeed possess the long-term self-renewal capacities *in vivo*, the CSCs of  
10  
11 interest are isolated from the xenograft tumors, and then serially injected into the mice.  
12  
13 Cell populations that can maintain long-term self-renewal properties (CSCs) will have  
14  
15 sustained tumor growth during multiple transplantations. Cell populations with a limited  
16  
17 self-renewal will lose their tumorigenicity upon serial xenografting (2, 31).  
18  
19  
20

21  
22 For the lineage tracing of CSC cells *in vivo*, a genetically modified mouse model  
23  
24 can be established where CSC populations are labeled by using CSC specific gene  
25  
26 reporters and monitored during tumor development in the living mice (32).  
27

28  
29 New approaches which facilitate genome editing such as transcription activator,  
30  
31 like effector nucleases (TALENs), zinc finger nucleases (ZFN) and the clustered  
32  
33 regularly interspaced palindromic repeats/Cas9 associated (CRISPR/Cas9) technologies  
34  
35 opened new possibilities to investigate endogenous gene functions at the genome-wide  
36  
37 scale and to establish a direct link between the cellular genome and cellular properties  
38  
39 including multipotency and self-renewal.  
40  
41  
42  
43

### 44 **3. Hallmarks of PCSC metabolism**

#### 45 **3. 1. Metabolism of normal and cancer prostate epithelial cells**

46  
47  
48 In contrast to other epithelial tissues, normal prostate epithelial cells have  
49  
50 alterations in glucose metabolism attributed to the main function of prostate gland: to  
51  
52 produce and secrete fluid that protects and nourishes sperm. Luminal compartment of  
53  
54 prostate gland produces and secretes a large amount of citrate into prostatic fluid. The  
55  
56  
57  
58  
59  
60



8

1  
2  
3 high level of citrate is important for the maintenance of sperm viability by  
4 supplementation with the source of energy and by calcium chelation (33). In most of  
5 normal tissues, citrate, which is produced in mitochondria or delivered into the cells by  
6 the membrane transporters, is utilized as a major substrate for energy production in  
7 tricarboxylic acid cycle (TCA) (34). High production of citrate in prostate glands is a  
8 consequence of low activity of mitochondrial aconitase (m,ACNT) and subsequent  
9 inhibition of citrate oxidation (35). In normal luminal cells, suppression of m,ACNT  
10 enzymatic activity is a result of a high mitochondrial concentration of zinc that is  
11 maintained by a high expression level of zinc transporter proteins (35, 36). As a result of  
12 the impaired citrate oxidation, normal prostate epithelial cells have a low level of TCA  
13 and glycolytic metabolism. In contrast to the normal luminal cells, malignant prostate  
14 cells contain a low level of mitochondrial zinc that abrogates the inhibition of ACNT  
15 activity and enables utilization of citrate in the metabolic pathways (34,36).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33         Reprogramming of cellular energy metabolism plays an important role in tumor  
34 initiation, progression and therapy resistance. To meet high energetic demands, fast  
35 growing tumor cells that exhibit the Warburg effect, need to reprogram their metabolic  
36 pathways for a high level of nutrient consumption that is especially true in case of  
37 metabolically active aggressive primary tumors and castration-resistant metastatic  
38 disease. These metabolic features of prostate tumors can be used in clinical setting for  
39 detection of metastatic disease and assessment of the therapeutic response using  
40 positron emission tomography (PET) for glucose uptake imaging with 2-[18F]Fluoro-2,  
41 deoxyglucose (FDG) (37). In addition to an increased glucose uptake, highly proliferative  
42 cancer cells require additional supplies for their biosynthesis that cannot be met by  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

9

1  
2  
3 glucose consumption. A significant proportion of the biosynthetic needs may be covered  
4  
5 by the metabolism of glutamine that is the most abundant amino acid in human plasma.  
6  
7  
8  
9

### 10 **3. 2. Glutamine metabolism in PCa**

11  
12 Glutamine is an important donor of nitrogen and carbon for the growth-promoting  
13  
14 pathways. Although most normal tissues can synthesize glutamine, it becomes  
15  
16 conditionally essential for the fast growing tissues (38, 39). A high demand for glutamine  
17  
18 is particularly true for tumors that acquire oncogene-dependent glutamine addiction  
19  
20 including prostate carcinomas (38, 39).  
21  
22

23  
24 Glutamine contributes to both energy producing pathways in cancer cells:  
25  
26 mitochondrial respiration and anaerobic glycolysis (40, 41). In addition, glutamine is  
27  
28 involved in maintaining homeostasis of the reactive oxygen species (ROS) and is  
29  
30 important for nucleotide and amino acid biosynthesis (40, 41). Beyond its role in cellular  
31  
32 metabolism, glutaminolysis also modulates many intracellular mechanisms that play a  
33  
34 pivotal role in cancer progression. These mechanisms include activation of the  
35  
36 mammalian target of rapamycin (mTOR) signaling pathway (42), promoting glycosylation  
37  
38 of the growth factor receptors required for their cell surface localization and signaling  
39  
40 activation (43), activation of the metabotropic glutamate receptor pathways as well as  
41  
42 inducing replicative immortality and resistance to cell death (40, 41).  
43  
44  
45

46  
47 The curative rate of radiation therapy that is one of the main treatment for PCa,  
48  
49 depends on its ability to induce irreparable DNA damage in tumor cells by direct DNA  
50  
51 ionization or through production of chemically reactive oxygen species (ROS) (44, 45).  
52  
53 During tumor growth, some of the tumor regions can outgrow their blood supplies and  
54  
55 therefore have a low oxygen tension, or hypoxia. Cancer cells residing in the hypoxic  
56  
57  
58  
59  
60

10

1  
2  
3 areas can be more shielded from the radiation-induced DNA damage through reduced  
4  
5 production of ROS and activation of the pro-survival signaling pathways such as  
6  
7 hypoxia-inducible factor (HIF) signaling (46). HIF1 is also associated with development  
8  
9 of PCa metastases (47) and activates transcription of genes involved in glycolytic flux  
10  
11 and Warburg effect (48). To defend against ROS-mediated oxidative stress, some  
12  
13 metabolic pathways including glutamine and pentose phosphate pathway (PPP) enable  
14  
15 cancer cells to produce a high level of glutathione (GSH) involved in scavenging and  
16  
17 detoxification of ROS (49). Recent work demonstrated that D,3-phosphoglycerate  
18  
19 dehydrogenase (PHGDH) that is one of the key enzymes to catabolize glutamate for  
20  
21 ATP and GSH synthesis, is required for the maintenance of breast CSC and metastasis,  
22  
23 and PHGDH knockdown was associated with reduced tumorigenicity (49).  
24  
25  
26  
27

28 The essential role of glutamine metabolism in cancer cell survival and  
29  
30 proliferation under nutrient-poor tumor microenvironment makes it an attractive target for  
31  
32 cancer therapy and tumor imaging, and [<sup>18</sup>F]-labelled, and hyperpolarized [<sup>5,13</sup>C]  
33  
34 analogues of glutamine are currently under development for localization of malignant  
35  
36 tissues including prostate tumors (50).  
37  
38  
39  
40  
41

### 42 **3.3. MYC dependent metabolic reprogramming and maintenance of PCSCs**

43

44 Although many cancer cells require glutamine for survival and growth, tumor cells  
45  
46 with enhanced expression of MYC oncogene are particularly dependent on glutamine  
47  
48 metabolism to sustain their viability. In these cells, deprivation of glutamine results in  
49  
50 depression of TCA cycle, decrease in ATP level, and apoptosis (38, 51). MYC is a broad  
51  
52 transcription regulator that activates the embryonic stem cell program in human cancer  
53  
54 and induces tumor initiating cells (52). Recent findings indicate that targeting of MYC  
55  
56  
57  
58  
59  
60

11

1  
2  
3 inhibits the maintenance of CSCs and tumorigenicity (53). MYC contributes to  
4  
5 metabolic adaptations of tumor cells which exhibit the Warburg effect by regulation of  
6  
7 the glucose transporter GLUT1 and the enzymes involved in the glucose metabolism  
8  
9 such as hexokinase 2 (HK2), phosphofructokinase (PFK1), enolase 1 (ENO1) and  
10  
11 lactate dehydrogenase A (LDHA) (54).  
12  
13

14 Together with androgen receptor (AR) and well established tumor driver mTOR,  
15  
16 MYC regulates expression of glutamine transporters genes *SLC1A4* and *SLC1A5*, which  
17  
18 are frequently overexpressed in PCa, and thereby increases glutamine uptake (55).  
19  
20 Through the suppression of miR,23a/b, MYC also regulates level of GLS1 glutaminase  
21  
22 that converts glutamine to glutamate at the first step of glutamine utilization (51).  
23  
24 Analysis of human prostate tissues has revealed upregulation of *MYC* mRNA in the  
25  
26 majority of primary PCa lesions (53). This overexpression of *MYC* can be attributed to  
27  
28 *MYC* oncogene amplification that occurs in up to 29% of hormone-refractory recurrent  
29  
30 prostate carcinomas (56). In addition, *MYC* expression can be regulated at the mRNA  
31  
32 level as a result of APC hypermethylation and Wnt/ $\beta$ ,catenin pathway activation,  
33  
34 deletion of FOXP3 gene as well as TMPRSS2,ERG rearrangement that activates ERG,  
35  
36 dependent transcription program (57,60). The single-step overexpression of *MYC* is  
37  
38 sufficient to bypass senescence and immortalize prostate cells derived from benign  
39  
40 prostate tissue specimens (61). Transgenic Hi,Myc mice that express human MYC in  
41  
42 the mouse prostate in response to androgen, first develop prostatic intraepithelial  
43  
44 neoplasia (PIN) followed by invasive adenocarcinoma (62). This process has a MYC  
45  
46 dose-dependent manner, and MYC-driven tumors share molecular signatures with  
47  
48 human PCa such as loss of Nkx3.1 tumor suppressor and upregulation of Pim,1 protein  
49  
50 kinase that increases energy metabolism and protein synthesis (62, 63). The two-step  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

12

1  
2  
3 transformation of prostate basal or luminal cells from benign prostate tissues either by  
4  
5 MYC overexpression and AKT activation, or by overexpression of MYC and knockout of  
6  
7 the tumor suppressor phosphatase and tensin homolog (PTEN) induces development of  
8  
9 heterogeneous tumors from both luminal and basal cell compartments (64,67). High  
10  
11 expression of MYC and loss of PTEN contribute to the androgen-independent growth  
12  
13 and are associated with highly invasive and metastatic prostate tumors (66,69).  
14  
15 Interestingly, MYC is a context-dependent regulator of the expression of glutamine  
16  
17 transporters *SLC1A4* and *SLC1A5*, and does not regulate these transporters in PTEN  
18  
19 wild-type tumors (55).  
20  
21  
22  
23  
24  
25

### 26 **3.4. Androgen signaling and prostate cancer metabolism**

27  
28 Dependence on androgen signaling is a hallmark of initial stages of prostate  
29  
30 tumor progression. Because of this, androgen deprivation therapy (ADT) is one of the  
31  
32 main treatments for PCa beside prostatectomy and radiotherapy. While most of the  
33  
34 patients initially respond to ADT, about 90% of them eventually develop androgen  
35  
36 refractory tumors with a fatal prognosis (70). Androgen-independent tumor progression  
37  
38 depends on the different mechanisms including *AR* gene amplification and gene  
39  
40 mutation, ligand-independent activation of AR signaling pathway and alterations in the  
41  
42 expression of AR coregulators leading to an increase in AR-dependent transcription  
43  
44 activity (71). Like MYC, AR regulates expression of many proteins involved in glutamine  
45  
46 metabolism including GLUT1, HK1/2 and calmodulin-dependent kinase kinase 2  
47  
48 (CAMKK2). CAMKK2 is highly upregulated in PCa and CAMKK2-dependent activation of  
49  
50 AMP-regulated kinase (AMPK) results in an increased 1-phosphofructokinase (PFK1)  
51  
52 activity and promotes glucose uptake and lactate production (72). Metformin that is the  
53  
54  
55  
56  
57  
58  
59  
60

13

1  
2  
3 first, line drug for treating diabetes enhances AMPK activity by inhibition of mitochondrial  
4  
5 complex I (73). Metformin treatment was clinically associated with a significant decrease  
6  
7 in early biochemical relapse and cancer specific mortality in PCa patients (74), and also  
8  
9 led to an increase in tumor oxygenation and response to radiotherapy in mice xenograft  
10  
11 models (74). Metformin combined with doxorubicin completely inhibits growth of PC3  
12  
13 PCa cells in mice xenografts (75). Metformin treatment of PC3, docetaxel, resistant (PC3,  
14  
15 DR) cells which have an increased oxidative metabolism, results in the inhibition of their  
16  
17 proliferation and invasiveness without affecting parental PC3 cells (76). However, the  
18  
19 effect of metformin on PCSCs has not been investigated so far. Interestingly, in the  
20  
21 above described Hi, Myc mice model of PCa progression, metformin suppressed AR,  
22  
23 dependent expression of MYC and inhibited development of PIN and PCa lesions (77).

24  
25  
26 An increase in MYC copy number in tumor cells was observed as a result of  
27  
28 androgen deprivation therapy in PCa patients (78). Experimental data showed that  
29  
30 overexpression of MYC antagonizes the AR, dependent transcription program and  
31  
32 confers growth advantage for tumor cells grown without androgens. Therefore, increase  
33  
34 in MYC expression might induce androgen, independent prostate tumor progression (69,  
35  
36  
37  
38  
39  
40 79).

### 41 42 43 44 **3.5. Metabolic reprogramming of prostate tumor epigenetics**

45  
46  
47 Interestingly, MYC expression level inversely correlates with global level of  
48  
49 H3K27me3 repressive histone mark in human PCa and MYC, driven mice prostate  
50  
51 tumors (80). Decreased level of H3K27me3 correlates with a higher Gleason score and  
52  
53 pathological stage. The basal compartment of normal prostate epithelium has a lower  
54  
55 level of H3K27me3 as compared to the luminal cells (80). In support to this observation,  
56  
57  
58  
59  
60

14

1  
2  
3 MYC expression and MYC-dependent transcriptional program were shown to be  
4  
5 upregulated in basal cells (81). Recent work revealed that normal stem cells such as  
6  
7 embryonic stem cells (ESCs) have an increased consumption of glutamine that is  
8  
9 utilized to maintain a high level of  $\alpha$ -ketoglutarate (AKG). AKG is a co-factor for the  
10  
11 Jumonji C domain-containing histone lysine demethylases as well as ten-eleven  
12  
13 translocation hydroxylases (82) that regulate DNA demethylation (83, 84). In ESC, AKG  
14  
15 promotes histone demethylation including H3K27me3 mark and therefore suppresses  
16  
17 differentiation (20, 85). Targeting glutamine uptake via inhibition of the major glutamine  
18  
19 transporter in cancer cells ASCT2 (SLC1A5) suppress tumor growth in PCa xenografts  
20  
21 (86). Prostate tumor initiating populations also exhibit a high dependence on  
22  
23 glutaminolysis. Recent studies employed two clonal populations derived from PC3 PCa  
24  
25 cells with different orthotopic and metastatic growth in xenograft models to characterize  
26  
27 metabolic features associated with PCSCs (87, 88). These studies showed that PC3  
28  
29 CSC-like cells exhibit a high level of anaerobic glycolysis. These cells have a high level  
30  
31 of lactate production and increased consumption of glutamine to compensate the  
32  
33 acidification derived from the Warburg effect through release of ammonia (88). In  
34  
35 support of this data, other studies showed that advanced PCa have an increased  
36  
37 glycolytic phenotype and a high activity of lactate dehydrogenase (LDH) that correlates  
38  
39 with poor clinical prognosis (25, 89).  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 **4. The role of CSC in prostate cancer progression**

##### 50 **4.1. A “vicious cycle” of prostate bone metastases**

51 Majority of PCa patients with advanced disease develop bone metastases (90).  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

15

1  
2  
3 disease is associated with a high risk of morbidity caused by the various complications  
4  
5 from bone metastases (93). Prostate bone metastases can produce factors that can  
6  
7 enhance both osteoblastic and osteoclastic activity and disrupt normal bone  
8  
9 homeostasis. In turn, the supportive sites which maintain survival and proliferation of  
10  
11 cancer cells in bone marrow are defined by special cytokines and growth factors  
12  
13 produced by osteoblast, osteoclasts and bone marrow stromal cells or released from the  
14  
15 bone matrix upon resorption. This feedback loop between the seeds (prostate tumor  
16  
17 cells) and soil (bone microenvironment) leads to a “vicious cycle” of tumor growth as  
18  
19 reviewed previously (94).  
20  
21  
22

23  
24 The bone microenvironment produces or releases various growth factors and  
25  
26 cytokines which bind to the receptors of prostate tumor cells and regulate their growth  
27  
28 and survivals. Among them are Wnt proteins that bind to the Frizzled receptor and its  
29  
30 LRP5/6 co-receptor and activates  $\beta$ -catenin dependent gene expression, C,X,C motif  
31  
32 chemokine ligand 12 (CXCL12) that binds to C,X,C chemokine receptor type 4  
33  
34 (CXCR4), as well as growth factors e.g. transforming growth factor beta (TGF $\beta$ ), insulin  
35  
36 like growth factor 1 (IGF1), bone morphogenetic proteins (BMPs) and fibroblast growth  
37  
38 factor (FGF) that promote metastatic growth (95).  
39  
40  
41

42  
43 In return, PCa cells in bone can produce several pro-osteolytic factors including  
44  
45 interleukins IL,6, IL,1, parathyroid hormone-related protein (PTHrP) and prostate  
46  
47 specific antigen (PSA) that stimulate formation of osteoclasts and promote resorption of  
48  
49 bone matrix. Unlike bone metastases from breast and myeloma tumors, PCa  
50  
51 metastases almost always form osteoblastic lesions (96). The factors released by PCa  
52  
53 cells in bone include signaling molecules affecting osteoblast proliferation or  
54  
55 differentiation such as WNT ligands, transforming growth factor, $\beta$  (TGF $\beta$ ), and  
56  
57  
58  
59  
60



16

1  
2  
3 osteoprotegerin (OPG) that regulate both, bone remodeling and tumorigenesis (96, 97).  
4  
5 OPG that is produced by PCa cells and by bone marrow, is an inhibitor of a TNF-related  
6  
7 apoptosis inducing ligand (TRAIL) and important survival factor in hormone independent  
8  
9 PCa cells (98). Interestingly, PSA has been shown to inhibit OPG expression and  
10  
11 increase mRNA expression of the receptor activator of nuclear factor kappa<sub>B</sub> ligand  
12  
13 (RANKL) that induces osteoclast differentiation (99). It worth to mention that in contrast  
14  
15 to primary tumors that are almost always PSA positive, up to 40% of prostate  
16  
17 metastases are negative for PSA expression (100, 101).  
18  
19  
20  
21  
22  
23

#### 24 **4.2. Metastatic spread as CSC evolution process**

25  
26 Metastatic spread is a multistep process that starts from invasion of cancer  
27  
28 through the basement membrane and entering the bloodstream (intravasation). At this  
29  
30 stage circulating tumor cells (CTCs) can be disseminated to distant organs. Some of  
31  
32 CTCs which escaped anoikis, immune clearance and mechanical stresses can leave the  
33  
34 bloodstream and enter the tissue in the distant organs in a process called extravasation.  
35  
36 At this stage these disseminated tumor cells (DTCs) can remain dormant at distant site  
37  
38 for a few years prior to metastatic progression (90, 102). Only a small subset of DTCs  
39  
40 can become metastasis initiating cells (MICs). Selection of DTCs toward a metastatic  
41  
42 genotype is driven by the microenvironmental conditions at distant site but also by the  
43  
44 factors from the primary tumors, which define the ability of DTCs to overcome tumor  
45  
46 latency and to form a metastatic tumor (90, 103,105). Metastasis formation can be  
47  
48 considered as an evolutionary process (Figure 1). Plasticity of the genetic and  
49  
50 epigenetic tumor makeups and selection of the most adapted tumor cells at the all  
51  
52 stages of metastatic tumor progression results in the development of cell inherent traits  
53  
54  
55  
56  
57  
58  
59  
60

17

1  
2  
3 that favor tumor dissemination (1, 91). CSCs that possess self-renewal properties and  
4  
5 genomic instability are considered to be an engine of tumor evolution. It is becoming  
6  
7 commonly accepted that tumor metastases are driven by the evolved populations of  
8  
9 CSCs at their worst. In support of this CTCs and DTCs express many CSC markers, and  
10  
11 metastasis initiating cells, MIC are sharing key CSC features including ability to self-  
12  
13 renew, to form tumors and to activate CSC specific signaling pathways as reviewed  
14  
15 recently (91) (Table 2). The gene signatures that are specific for CSCs correlate with  
16  
17 tumor progression and development of prostate tumor metastasis (88, 106).  
18  
19 Enumeration of CTCs in blood, and DTCs in bone marrow of PCa patients have  
20  
21 prognostic and predictive value in PCa (89, 90, 107). Metastatic tumors, CTCs and  
22  
23 DTCs also show varying degrees of concordance with molecular signatures of primary  
24  
25 tumor of origin (108,112). Recent study based on the analysis of a large set of RNA  
26  
27 expression data from more than 4000 clinical PCa specimens demonstrates that tumor  
28  
29 subtype which exhibit a high expression of luminal markers EZH2, AR, MK167 and low  
30  
31 expression of luminal markers NKX3.1, PSA, ERG, KLK2 and basal markers e.g. TP63  
32  
33 and KRT5 is associated with the highest risk of progression to metastatic disease (113).  
34  
35 Interestingly, this gene signature was highly expressed in 58% of CTCs from patients  
36  
37 with antiandrogen therapy-resistant tumors (113). This study demonstrated that  
38  
39 molecular characterization of CTCs taken by noninvasive “liquid biopsy” can be used to  
40  
41 identify the patients at risk of metastatic disease and treatment selection. These results  
42  
43 are consistent with previous study showed that PSA negative ( $PSA^{low}$ ) prostate tumor  
44  
45 cells are resistant to chemotherapy, androgen deprivation and stress simulation, and  
46  
47 exhibit long-term tumor propagation capacity (3). Another study showed that CTCs and  
48  
49 DTCs cells isolated from mouse xenografts of human prostate tumors exhibit increased  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

18

1  
2  
3 potential to metastasize *in vivo* and resistance to the chemotherapeutic agents  
4  
5 mitoxantrone and doxorubicin (114).  
6  
7  
8  
9

#### 10 **4.3. Common mechanism for metastasis and therapy resistance**

11  
12 A growing body of evidence suggests mechanisms connecting the development  
13  
14 of therapy resistance and metastatic phenotypes during tumor progression (115,117). In  
15  
16 particular, the CXCL12/CXCR4 axis is shown to regulate extravasation and guidance of  
17  
18 PCa cells to bone. Furthermore, activation of the CXCL12/CXCR4 and WNT/ $\beta$ ,catenin  
19  
20 signaling pathways which are important regulators of PCSCs can promote tumor  
21  
22 radioresistance and contribute to the development of skeletal metastases (20, 118,120).  
23  
24 Aldehyde dehydrogenase (ALDH) activity can be used to enrich for PCa cells with  
25  
26 increased tumorigenic and metastatic capability *in vivo* and high radioresistance (20,  
27  
28 121, 122). ALDH plays an important role in the cellular response to oxidative stress and  
29  
30 can potentially serve as one of the pro-survival mechanisms in CTCs enabling them to  
31  
32 withstand oxidative stress in the bloodstream (123). Although several ALDH isoforms  
33  
34 are described to be highly expressed in PCa, only ALDH1A1 gene expression was  
35  
36 significantly correlated with ALDH activity and was increased at higher levels in  
37  
38 advanced-stage compared to low-stage PCa and benign prostate hyperplasia (124).  
39  
40 WNT ligands produced by tumor cells or by the bone cells are acting in an autocrine or  
41  
42 paracrine fashion by enhancing tumor cell proliferation and inhibiting apoptosis (125). In  
43  
44 addition, WNT ligands have a paracrine effect and induce osteoblastic activity promoting  
45  
46 bone mineralization in PCa bone metastases, whereas WNT inhibitors promote an  
47  
48 osteolytic environment (125, 126). Activation of canonical  $\beta$ ,catenin dependent WNT  
49  
50 signaling is associated with malignant transformation, metastasis and radioresistance of  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

19

1  
2  
3 PCa (20, 127). In different cancer models, WNT signaling pathway has been shown to  
4  
5 regulate expression of CXCR4 and ALDH1A1 genes (20, 128, 129) whereas canonical  
6  
7 WNT signaling pathway can be activated by CXCR4 , dependent mechanisms (130,  
8  
9 131). Bone targeted therapies such as bisphosphonate drugs, exhibit inhibitory effects  
10  
11 on osteoclast-mediated bone resorption but also inhibit the growth of PCa cells (132,  
12  
13 133). Recent studies showed that bisphosphonate treatment regulates the WNT  
14  
15 signaling pathway in PCa e.g. by inhibition of *WNT5A* and *FZD5* gene expression (134).  
16  
17 TGF $\beta$  signaling activated in bone metastases regulates the prometastatic and  
18  
19 pro-survival properties of PCa cells including expression of CXCR4 and increase of  
20  
21 ALDH activity (122, 135,137). PCa cells have deregulated expression of the  
22  
23 transmembrane extracellular matrix receptors integrins (138) that play a critical role in  
24  
25 prostate tumor cell invasion and metastatic development (139). Tumor cell population  
26  
27 positive for  $\alpha 2\beta 1$  integrin expression is enriched for prostate tumor initiating cells (30,  
28  
29 140). Recent studies showed that integrin signaling might also contribute to the  
30  
31 resistance to therapeutic androgen ablation and radiotherapy in PCa cells (141, 142).  
32  
33  
34  
35  
36

37  
38 Therefore, activation of the signaling pathways detected on the genomic and  
39  
40 transcriptomic levels in DTCs, CTCs from the blood of the patients and CSCs in primary  
41  
42 tumors can be prognostic for metastasis development and, on other hand, can be  
43  
44 involved in the response of primary and metastatic tumors to therapy. Further studies  
45  
46 are warranted to investigate the molecular mechanisms regulating metastasis, initiating  
47  
48 and therapy resistant prostate tumor cells and characterize their clinical relevance.  
49  
50  
51  
52

## 53 54 **5. Summary and future directions**

55  
56  
57  
58  
59  
60

1  
2  
3 PCSCs that possess self-renewal properties and genomic instability might serve  
4  
5 as a driving force of tumor evolution and metastatic dissemination. A number of recent  
6  
7 studies demonstrated that analysis of CSCs in patients' tumors might serve as  
8  
9 prognostic or predictive biomarker (143, 144). In combination with other extrinsic and  
10  
11 intrinsic parameters that might affect the properties and complexity of CSC populations,  
12  
13 for example heterogeneity indices and hypoxia, these markers could in the future be  
14  
15 used for patient stratification and more personalized treatment selection. There is an  
16  
17 increasing body of evidence that PCSCs possess a higher chemo- and radioresistance  
18  
19 compared to the tumor bulk (3, 20, 145). In support to these studies, inhibition of the  
20  
21 signaling pathways that play a role in the maintenance of PCSCs such as WNT/ $\beta$ -  
22  
23 catenin and PI3K/AKT results in the sensitization of the experimental tumor models to  
24  
25 the different types of therapy (121, 145, 146). Understanding the genetic relationship  
26  
27 between PCSCs, CTCs, DTCs and MICs and better characterization of the MIC  
28  
29 phenotypes and properties might become pivotal in the future for prevention of tumor  
30  
31 cell dissemination and treatment of metastatic disease that is not curable with current  
32  
33 standard therapies.  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Acknowledgement**

43  
44 Work in Tang lab was supported, in part, by grants from the US National Institutes  
45  
46 of Health (NIH) (R01,CA155693), Department of Defense (W81XWH,13,1,0352,  
47  
48 W81XWH,14,1,0575, and W81XWH,16,1,0575), and the Chinese Ministry of Science  
49  
50 and Technology (MOST) grant 2016YFA0101203, and by RPCI and NCI center grant  
51  
52 P30CA016056. Work in A.D. lab is partially supported by grants from Deutsche  
53  
54  
55  
56  
57  
58  
59  
60

21

Forschungsgemeinschaft (DFG) (273676790), from Wilhelm Sander-Stiftung (2017.106.1) and BMBF (Grant No. 03Z1NN11).

### References

1. Kreso A, Dick JE. Evolution of the cancer stem cell model. *Cell stem cell*. 2014;14(3):275-91.
2. Rycaj K, Tang DG. Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations. *Cancer research*. 2015;75(19):4003-11.
3. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. *Cell stem cell*. 2012;10(5):556-69.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer research*. 2005;65(23):10946-51.
5. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. *Cancer research*. 2005;65(15):6640-50.
6. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. *Cancer research*. 2005;65(14):6207-19.
7. Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. *PloS one*. 2012;7(8):e42564.
8. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. *Laboratory investigation; a journal of technical methods and pathology*. 2010;90(2):234-44.
9. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. *British journal of cancer*. 2008;98(4):756-65.
10. Dubrovskaya A, Elliott J, Salamone RJ, Teleguev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. *PloS one*. 2012;7(2):e31226.
11. Buczek ME, Reeder SP, Regad T. Identification and Isolation of Cancer Stem Cells Using NANOG-EGFP Reporter System. *Methods in molecular biology*. 2018;1692:139-48.
12. Della Donna L, Lagadec C, Pajonk F. Radioresistance of prostate cancer cells with low proteasome activity. *The Prostate*. 2012;72(8):868-74.
13. Tang B, Raviv A, Esposito D, Flanders KC, Daniel C, Nghiem BT, et al. A flexible reporter system for direct observation and isolation of cancer stem cells. *Stem cell reports*. 2015;4(1):155-69.
14. Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, et al. Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. *Stem cells*. 2015;33(7):2114-25.
15. Torre-Healy LA, Berezovsky A, Lathia JD. Isolation, Characterization, and Expansion of Cancer Stem Cells. *Methods in molecular biology*. 2017;1553:133-43.
16. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. *Oncogene*. 2011;30(36):3833-45.
17. Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, Ping YF, et al. Strategies for isolating and enriching cancer stem cells: well begun is half done. *Stem cells and development*. 2013;22(16):2221-39.
18. Hristova NR, Tagscherer KE, Fassl A, Kopitz J, Roth W. Notch1-dependent regulation of p27 determines cell fate in colorectal cancer. *International journal of oncology*. 2013;43(6):1967-75.

22

19. Skvortsov S, Debbage P, Skvortsova I. Proteomics of cancer stem cells. *International journal of radiation biology*. 2014;90(8):653-8.
20. Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Telegeev GD, et al. Aldehyde Dehydrogenase Is Regulated by beta-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. *Cancer research*. 2015;75(7):1482-94.
21. Khan MI, Czarnecka AM, Helbrecht I, Bartnik E, Lian F, Szczylik C. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. *Stem cell research & therapy*. 2015;6:178.
22. Liu WH, Qian NS, Li R, Dou KF. Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. *Toxicology in vitro : an international journal published in association with BIBRA*. 2010;24(2):538-45.
23. Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. Therapy-induced enrichment of putative lung cancer stem-like cells. *International journal of cancer*. 2014;134(6):1270-8.
24. Vlashi E, Chen AM, Boyrie S, Yu G, Nguyen A, Brower PA, et al. Radiation-Induced Dedifferentiation of Head and Neck Cancer Cells Into Cancer Stem Cells Depends on Human Papillomavirus Status. *International journal of radiation oncology, biology, physics*. 2016;94(5):1198-206.
25. Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. *The Journal of pathology*. 2015;236(4):517-30.
26. Li Q, Rycaj K, Chen X, Tang DG. Cancer stem cells and cell size: A causal link? *Semin Cancer Biol*. 2015;35:191-9.
27. Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, et al. Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22(17):4505-16.
28. Kuch V, Schreiber C, Thiele W, Umansky V, Sleeman JP. Tumor-initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by long-term culturing as adherent monolayers. *International journal of cancer*. 2013;132(3):E94-105.
29. Matilainen H, Yu XW, Tang CW, Berridge MV, McConnell MJ. Sphere formation reverses the metastatic and cancer stem cell phenotype of the murine mammary tumour 4T1, independently of the putative cancer stem cell marker Sca-1. *Cancer letters*. 2012;323(1):20-8.
30. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. *Cancer research*. 2007;67(14):6796-805.
31. Beck B, Blanpain C. Unravelling cancer stem cell potential. *Nature reviews Cancer*. 2013;13(10):727-38.
32. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, et al. Single luminal epithelial progenitors can generate prostate organoids in culture. *Nature cell biology*. 2014;16(10):951-61, 1-4.
33. Ford WC, Harrison A. The role of citrate in determining the activity of calcium ions in human semen. *International journal of andrology*. 1984;7(3):198-202.
34. Mycielska ME, Patel A, Rizaner N, Mazurek MP, Keun H, Patel A, et al. Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. *BioEssays : news and reviews in molecular, cellular and developmental biology*. 2009;31(1):10-20.
35. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. *The Journal of biological chemistry*. 1997;272(46):28875-81.
36. Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A, et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. *Molecular cancer*. 2005;4:32.

- 1
- 2
- 3 37. Jadvar H. Is There Use for FDG-PET in Prostate Cancer? *Seminars in nuclear medicine*. 2016;46(6):502-6.
- 4
- 5 38. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a
- 6 transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.
- 7 *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(48):18782-7.
- 8
- 9 39. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and
- 10 clinical opportunities. *The Journal of clinical investigation*. 2013;123(9):3678-84.
- 11
- 12 40. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes
- 13 modulates metabolism and senescence. *Nature*. 2013;493(7434):689-93.
- 14
- 15 41. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine
- 16 metabolism via TCA cycling for proliferation and survival in B cells. *Cell metabolism*. 2012;15(1):110-21.
- 17
- 18 42. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of
- 19 amino acids regulates mTOR and autophagy. *Cell*. 2009;136(3):521-34.
- 20
- 21 43. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The hexosamine
- 22 biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes &*
- 23 *development*. 2010;24(24):2784-99.
- 24
- 25 44. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and
- 26 prolonged cell injury. *Cancer letters*. 2012;327(1-2):48-60.
- 27
- 28 45. Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-
- 29 induced signal transduction mechanisms. *Oncogene*. 2003;22(37):5734-54.
- 30
- 31 46. Peitzsch C, Perrin R, Hill RP, Dubrovskaya A, Kurth I. Hypoxia as a biomarker for radioresistant
- 32 cancer stem cells. *International journal of radiation biology*. 2014;90(8):636-52.
- 33
- 34 47. Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, et al. The role of hypoxia-
- 35 inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers. *PloS one*.
- 36 2013;8(1):e54251.
- 37
- 38 48. Dang CV. The interplay between MYC and HIF in the Warburg effect. *Ernst Schering Foundation*
- 39 *symposium proceedings*. 2007(4):35-53.
- 40
- 41 49. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovskaya A. Discovery of the cancer stem
- 42 cell related determinants of radioresistance. *Radiotherapy and oncology : journal of the European*
- 43 *Society for Therapeutic Radiology and Oncology*. 2013;108(3):378-87.
- 44
- 45 50. Tang C, Tang G, Gao S, Liu S, Wen F, Yao B, et al. Radiosynthesis and preliminary biological
- 46 evaluation of N-(2-[18F]fluoropropionyl)-L-glutamine as a PET tracer for tumor imaging. *Oncotarget*.
- 47 2016;7(23):34100-11.
- 48
- 49 51. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b
- 50 enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature*.
- 51 2009;458(7239):762-5.
- 52
- 53 52. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides
- 54 creation of epithelial cancer stem cells. *Cell stem cell*. 2008;2(4):333-44.
- 55
- 56 53. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and
- 57 Prostate Cancer. *Genes & cancer*. 2010;1(6):617-28.
- 58
- 59 54. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic
- 60 opportunities. *Clinical cancer research : an official journal of the American Association for Cancer*
- Research*. 2009;15(21):6479-83.
- 51 55. White MA, Lin C, Rajapakse K, Dong J, Shi Y, Tsouko E, et al. Glutamine Transporters Are Targets
- 52 of Multiple Oncogenic Signaling Pathways in Prostate Cancer. *Molecular cancer research : MCR*.
- 53 2017;15(8):1017-28.
- 54
- 55 56. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory
- 56 recurrent prostate carcinomas. *The American journal of pathology*. 1998;153(1):141-8.
- 57
- 58
- 59
- 60



- 1
- 2
- 3 57. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a
- 4 common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial
- 5 differentiation. *Oncogene*. 2008;27(40):5348-53.
- 6 58. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. *European*
- 7 *journal of cancer*. 2005;41(6):858-87.
- 8 59. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, et al. Somatic single hits inactivate the X-linked
- 9 tumor suppressor FOXP3 in the prostate. *Cancer cell*. 2009;16(4):336-46.
- 10 60. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation
- 11 arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic
- 12 tumor heterogeneity. *Cancer research*. 2008;68(21):8954-67.
- 13 61. Gil J, Kerai P, Lleontart M, Bernard D, Cigudosa JC, Peters G, et al. Immortalization of primary human
- 14 prostate epithelial cells by c-Myc. *Cancer research*. 2005;65(6):2179-85.
- 15 62. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven
- 16 murine prostate cancer shares molecular features with human prostate tumors. *Cancer cell*.
- 17 2003;4(3):223-38.
- 18 63. Beharry Z, Mahajan S, Zemsanova M, Lin YW, Tholanikunnel BG, Xia Z, et al. The Pim protein kinases
- 19 regulate energy metabolism and cell growth. *Proceedings of the National Academy of Sciences of the United*
- 20 *States of America*. 2011;108(2):528-33.
- 21 64. Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, et al. Prostate epithelial cell of origin
- 22 determines cancer differentiation state in an organoid transformation assay. *Proceedings of the National*
- 23 *Academy of Sciences of the United States of America*. 2016;113(16):4482-7.
- 24 65. Zhang D, Lin K, Lu Y, Rycak K, Zhong Y, Chao HP, et al. Developing a Novel Two-Dimensional Culture
- 25 System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate
- 26 Cancer. *Stem cells translational medicine*. 2017;6(3):748-60.
- 27 66. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, et al. Prostate cancer originating
- 28 in basal cells progresses to adenocarcinoma propagated by luminal-like cells. *Proceedings of the National*
- 29 *Academy of Sciences of the United States of America*. 2013;110(50):20111-6.
- 30 67. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc Drives
- 31 Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. *Cancer cell*.
- 32 2016;29(4):536-47.
- 33 68. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandralapaty S, et al. Reciprocal
- 34 feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer cell*.
- 35 2011;19(5):575-86.
- 36 69. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate
- 37 cancer cell growth. *The Journal of clinical investigation*. 2003;112(11):1724-31.
- 38 70. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation
- 39 therapy: mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene*.
- 40 2013;32(49):5501-11.
- 41 71. Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanisms of Androgen-Independent Prostate
- 42 Cancer. *Ejifcc*. 2014;25(1):42-54.
- 43 72. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels
- 44 prostate cancer by regulating central metabolism and biosynthesis. *The EMBO journal*.
- 45 2011;30(13):2719-33.
- 46 73. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in
- 47 mechanism of metformin action. *The Journal of clinical investigation*. 2001;108(8):1167-74.
- 48 74. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming metabolism
- 49 with metformin improves tumor oxygenation and radiotherapy response. *Clinical cancer research : an*
- 50 *official journal of the American Association for Cancer Research*. 2013;19(24):6741-50.
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 75. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for  
4 prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer research*.  
5 2011;71(9):3196-201.  
6  
7 76. Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, et al. Metabolic shift toward  
8 oxidative phosphorylation in docetaxel resistant prostate cancer cells. *Oncotarget*.  
9 2016;7(38):61890-904.  
10 77. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, et al. Metformin targets c-MYC  
11 oncogene to prevent prostate cancer. *Carcinogenesis*. 2013;34(12):2823-32.  
12 78. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, et al. FISH analysis of gene  
13 aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after  
14 androgen deprivation therapy. *Laboratory investigation; a journal of technical methods and pathology*.  
15 2000;80(9):1455-64.  
16 79. Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, et al. c-Myc Antagonises the  
17 Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.  
18 *EBioMedicine*. 2017;18:83-93.  
19 80. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, et al. Global levels of H3K27me3  
20 track with differentiation in vivo and are deregulated by MYC in prostate cancer. *The American journal*  
21 *of pathology*. 2012;181(2):560-9.  
22 81. Zhang D, Park D, Zhong Y, Lu Y, Rycaj K, Gong S, et al. Stem cell and neurogenic gene-expression  
23 profiles link prostate basal cells to aggressive prostate cancer. *Nature communications*. 2016;7:10798.  
24 82. Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic  
25 hallmarks of localized, non-indolent prostate cancer. *Nature*. 2017;541(7637):359-64.  
26 83. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, et al. Histone  
27 demethylation by a family of JmjC domain-containing proteins. *Nature*. 2006;439(7078):811-6.  
28 84. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to  
29 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*.  
30 2010;466(7310):1129-33.  
31 85. Peitzsch C, Cojoc M, Hein L, Kurth I, Mbert K, Trautmann F, et al. An epigenetic reprogramming  
32 strategy to re-sensitize radioresistant prostate cancer cells. *Cancer research*. 2016.  
33 86. Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-  
34 mediated glutamine uptake blocks prostate cancer growth and tumour development. *The Journal of*  
35 *pathology*. 2015;236(3):278-89.  
36 87. Celia-Terrassa T, Meca-Cortes O, Mateo F, Martinez de Paz A, Rubio N, Arnal-Estape A, et al.  
37 Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating  
38 cells. *The Journal of clinical investigation*. 2012;122(5):1849-68.  
39 88. Aguilar E, Marin de Mas I, Zodda E, Marin S, Morrish F, Selivanov V, et al. Metabolic  
40 Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the  
41 Epithelial-Mesenchymal Transition Program. *Stem cells*. 2016;34(5):1163-76.  
42 89. Heller G, Fizazi K, McCormack R, Molina A, MacLean D, Webb IJ, et al. The Added Value of  
43 Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic  
44 Castration-Resistant Prostate Cancer Population. *Clinical cancer research : an official journal of the*  
45 *American Association for Cancer Research*. 2017;23(8):1967-73.  
46 90. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, et al. Perioperative  
47 activation of disseminated tumor cells in bone marrow of patients with prostate cancer. *Journal of*  
48 *clinical oncology : official journal of the American Society of Clinical Oncology*. 2009;27(10):1549-56.  
49 91. Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovskaya A. Cancer stem cells: The root of tumor  
50 recurrence and metastases. *Semin Cancer Biol*. 2017;44:10-24.  
51 92. Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nature reviews Cancer*.  
52 2006;6(6):449-58.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 93. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate  
4 cancer: clinical implications. *Best practice & research Clinical endocrinology & metabolism.*  
5 2008;22(2):341-55.
- 6 94. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies.  
7 *Nature reviews Clinical oncology.* 2011;8(6):357-68.
- 8 95. Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL. Bone and prostate cancer cell interactions in  
9 metastatic prostate cancer. *BJU international.* 2007;99(4):735-42.
- 10 96. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nature reviews Cancer.*  
11 2005;5(1):21-8.
- 12 97. Coxon JP, Oades GM, Colston KW, Kirby RS. Advances in the use of bisphosphonates in the prostate  
13 cancer setting. *Prostate cancer and prostatic diseases.* 2004;7(2):99-104.
- 14 98. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human  
15 prostate cancer cells. *Cancer research.* 2002;62(6):1619-23.
- 16 99. Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, et al. Prostate-specific antigen  
17 modulates genes involved in bone remodeling and induces osteoblast differentiation of human  
18 osteosarcoma cell line SaOS-2. *Clinical cancer research : an official journal of the American Association for*  
19 *Cancer Research.* 2006;12(5):1420-30.
- 20 100. Bernacki KD, Fields KL, Roh MH. The utility of PSMA and PSA immunohistochemistry in the cytologic  
21 diagnosis of metastatic prostate carcinoma. *Diagnostic cytopathology.* 2014;42(7):570-5.
- 22 101. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic  
23 adenocarcinoma of the prostate. *The American journal of surgical pathology.*  
24 2007;31(9):1351-5.
- 25 102. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in  
26 prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical  
27 recurrence. *Clinical cancer research : an official journal of the American Association for Cancer Research.*  
28 2009;15(2):677-83.
- 29 103. Lam HM, Vessella RL, Morrissey C. The role of the microenvironment-dormant prostate  
30 disseminated tumor cells in the bone marrow. *Drug discovery today Technologies.* 2014;11:41-7.
- 31 104. Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, et al. HER2 and EGFR  
32 Overexpression Support Metastatic Progression of Prostate Cancer to Bone. *Cancer research.*  
33 2017;77(1):74-85.
- 34 105. Karlsson T, Lundholm M, Widmark A, Persson E. Tumor Cell-Derived Exosomes from the Prostate  
35 Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation. *PloS one.*  
36 2016;11(11):e0166284.
- 37 106. Mazzoleni S, Jachetti E, Morosini S, Grioni M, Piras IS, Pala M, et al. Gene signatures distinguish  
38 stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate  
39 lesions and predict the malignancy of human tumors. *Stem cells translational medicine.* 2013;2(9):678-89.
- 40 107. Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, et al. Decline in Circulating Tumor Cell  
41 Count and Treatment Outcome in Advanced Prostate Cancer. *European urology.* 2016;70(6):985-92.
- 42 108. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a  
43 prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PloS one.*  
44 2013;8(6):e66855.
- 45 109. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature  
46 predicting therapy failure in patients with multiple types of cancer. *The Journal of clinical investigation.*  
47 2005;115(6):1503-21.
- 48 110. Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, et al. Genomic alterations  
49 indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.  
50 *Cancer research.* 2008;68(14):5599-608.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60

111. Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. *Oncotarget*. 2015;6(42):44781-93.
112. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. *British journal of cancer*. 2015;113(8):1225-33.
113. You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, et al. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. *Cancer research*. 2016;76(17):4948-58.
114. Pavese JM, Bergan RC. Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. *Cancer letters*. 2014;352(2):179-86.
115. Hara T, Iwadate M, Tachibana K, Waguri S, Takenoshita S, Hamada N. Metastasis of breast cancer cells to the bone, lung, and lymph nodes promotes resistance to ionizing radiation. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]*. 2017.
116. Zakaria R, Platt-Higgins A, Rathi N, Crooks D, Brodbelt A, Chavredakis E, et al. Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response. *British journal of cancer*. 2016;114(10):1101-8.
117. Rofstad EK. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. *Cancer research*. 1992;52(16):4453-7.
118. Trautmann F, Cojoc M, Kurth I, Melin N, Bouchez LC, Dubrovskaya A, et al. CXCR4 as biomarker for radioresistant cancer stem cells. *International journal of radiation biology*. 2014;90(8):687-99.
119. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2005;20(2):318-29.
120. Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, et al. Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. *Cancer research*. 2017;77(6):1331-44.
121. Peitzsch C, Cojoc M, Hein L, Kurth I, Mabert K, Trautmann F, et al. An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. *Cancer research*. 2016;76(9):2637-51.
122. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. *Clinical & experimental metastasis*. 2011;28(7):615-25.
123. Singh S, Bocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. *Free radical biology & medicine*. 2013;56:89-101.
124. Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2013;19(19):5361-71.
125. Sottnik JL, Hall CL, Zhang J, Keller ET. Wnt and Wnt inhibitors in bone metastasis. *BoneKey reports*. 2012;1:101.
126. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. *Journal of cellular biochemistry*. 2006;97(4):661-72.
127. Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. *Nature reviews Urology*. 2017;14(11):683-96.
128. Holland JD, Gyorffy B, Vogel R, Eckert K, Valenti G, Fang L, et al. Combined Wnt/beta-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. *Cell reports*. 2013;5(5):1214-27.
129. Aman A, Piotrowski T. Wnt/beta-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. *Developmental cell*. 2008;15(5):749-61.

- 1  
2  
3 130. Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, et al. SDF-1/CXCR4 promotes epithelial-mesenchymal  
4 transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway.  
5 *Cancer letters*. 2014;354(2):417-26.
- 6 131. Zhao S, Wang J, Qin C. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic  
7 cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. *Journal of*  
8 *experimental & clinical cancer research : CR*. 2014;33:103.
- 9 132. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits  
10 inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. *Clinical cancer research : an*  
11 *official journal of the American Association for Cancer Research*. 2003;9(1):295-306.
- 12 133. Tuomela JM, Valta MP, Vaananen K, Harkonen PL. Alendronate decreases orthotopic PC-3 prostate  
13 tumor growth and metastasis to prostate-draining lymph nodes in nude mice. *BMC cancer*. 2008;8:81.
- 14 134. Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, Fuessel S, et al. Expression profile of WNT  
15 molecules in prostate cancer and its regulation by aminobisphosphonates. *Journal of cellular biochemistry*.  
16 2011;112(6):1593-600.
- 17 135. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting  
18 cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. *Cancer*  
19 *research*. 2007;67(9):4244-53.
- 20 136. Fournier PG, Juarez P, Jiang G, Clines GA, Niewolna M, Kim HS, et al. The TGF-beta Signaling  
21 Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. *Cancer cell*. 2015;27(6):809-21.
- 22 137. Caley MP, Kogianni G, Adamarek A, Gronau JH, Rodriguez-Teja M, Fonseca AV, et al. TGFbeta1-  
23 Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone  
24 metastasis. *The Journal of pathology*. 2012;226(5):775-83.
- 25 138. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. *Endocrine-related*  
26 *cancer*. 2008;15(3):657-64.
- 27 139. Harryman WL, Hinton JP, Rubenstein CP, Singh P, Nagle RB, Parker SJ, et al. The Cohesive  
28 Metastasis Phenotype in Human Prostate Cancer. *Biochimica et biophysica acta*. 2016;1866(2):221-31.
- 29 140. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct microRNA expression profiles in  
30 prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. *Cancer research*.  
31 2012;72(13):3393-404.
- 32 141. Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, et al. alphavbeta6 Integrin Promotes Castrate-Resistant  
33 Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. *Cancer research*.  
34 2016;76(17):5163-74.
- 35 142. Goel HL, Sayeed A, Breen M, Zarif MJ, Garlick DS, Leav I, et al. beta1 integrins mediate resistance to  
36 ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. *Journal of cellular physiology*.  
37 2013;228(7):1601-9.
- 38 143. Krause M, Dubrovskaya A, Linge A, Baumann M. Cancer stem cells: Radioresistance, prediction of  
39 radiotherapy outcome and specific targets for combined treatments. *Advanced drug delivery reviews*.  
40 2017;109:63-73.
- 41 144. Butof R, Dubrovskaya A, Baumann M. Clinical perspectives of cancer stem cell research in radiation  
42 oncology. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and*  
43 *Oncology*. 2013;108(3):388-96.
- 44 145. Dubrovskaya A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of  
45 PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.  
46 *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(1):268-73.
- 47 146. Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, et al. Targeting Cancer Stem Cells in  
48 Castration-Resistant Prostate Cancer. *Clinical cancer research : an official journal of the American*  
49 *Association for Cancer Research*. 2016;22(3):670-9.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

147. Shi X, Gipp J, Dries M, Bushman W. Prostate progenitor cells proliferate in response to castration. *Stem cell research*. 2014;13(1):154-63.
148. Zhang Y, Huang Y, Jin Z, Li X, Li B, Xu P, et al. A convenient and effective strategy for the enrichment of tumor-initiating cell properties in prostate cancer cells. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2016;37(9):11973-81.
149. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(52):20882-7.
150. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. *Cancer letters*. 2010;291(1):1-13.
151. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer research*. 2006;66(19):9339-44.
152. Hanrahan K, O'Neill A, Prencipe M, Bugler J, Murphy L, Fabre A, et al. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. *Molecular oncology*. 2017;11(3):251-65.
153. Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, et al. Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. *Cell cycle*. 2010;9(6):1194-206.
154. Li D, Fu Z, Chen R, Zhao X, Zhou Y, Zeng B, et al. Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. *Oncotarget*. 2015;6(31):31151-63.
155. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. *Science*. 2010;329(5991):568-71.
156. Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. *Cancer research*. 2014;74(4):1227-37.
157. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. *Stem cells*. 2012;30(6):1076-86.
158. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, et al. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. *Oncotarget*. 2017;8(42):71447-55.
159. Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, et al. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. *British journal of cancer*. 2015;112(7):1166-74.
160. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncol*. 2015;1(5):582-91.
161. Scher HI, Graf RP, Schreiber NA, McLaughlin B, Jendrisak A, Wang Y, et al. Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. *Cancer research*. 2017;77(20):5687-98.
162. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. *JAMA Oncol*. 2016;2(11):1441-9.
163. Carlsson A, Kuhn P, Luttmann MS, Dizon KK, Troncoso P, Corn PG, et al. Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2017;23(7):1722-32.

- 1  
2  
3 164. Shahriari K, Shen F, Worrede-Mahdi A, Liu Q, Gong Y, Garcia FU, et al. Cooperation among  
4 heterogeneous prostate cancer cells in the bone metastatic niche. *Oncogene*. 2017;36(20):2846-56.
- 5 165. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen  
6 Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. *Cancer cell*.  
7 2017;32(4):474-89 e6.
- 8 166. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial  
9 cells to androgen withdrawal and replacement. *The Prostate*. 1987;11(3):229-42.
- 10 167. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, et al. Androgen receptor signaling in  
11 circulating tumor cells as a marker of hormonally responsive prostate cancer. *Cancer discovery*.  
12 2012;2(11):995-1003.
- 13 168. Leon-Mateos L, Casas H, Abalo A, Vieito M, Abreu M, Anido U, et al. Improving circulating tumor  
14 cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.  
15 *Oncotarget*. 2017;8(33):54708-21.
- 16 169. Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, et al. Therapy-induced developmental  
17 reprogramming of prostate cancer cells and acquired therapy resistance. *Oncotarget*.  
18 2017;8(12):18949-67.
- 19 170. Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Swierczewska M, Budna J, et al. Multiplex  
20 Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.  
21 *Clinical chemistry*. 2017.
- 22 171. Guzvic M, Braun B, Ganzer R, Burger M, Nerlich M, Winkler S, et al. Combined genome and  
23 transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients  
24 reveals unexpected transcriptomes. *Cancer research*. 2014;74(24):7383-94.
- 25 172. Karthaus WR, Iaquinata PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, et al. Identification of  
26 multipotent luminal progenitor cells in human prostate organoid cultures. *Cell*. 2014;159(1):163-75.
- 27 173. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Australian Prostate Cancer B, et al.  
28 Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. *Stem cells*.  
29 2012;30(6):1087-96.
- 30 174. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial  
31 stem cell that is a cell of origin for prostate cancer. *Nature*. 2009;461(7263):495-500.
- 32 175. Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh H, et al. EMT circulating tumor cells detected by  
33 cell-surface vimentin are associated with prostate cancer progression. *Oncotarget*. 2017;8(30):49329-37.
- 34 176. Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, et al. The Novel Association of Circulating Tumor  
35 Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis. *Clinical cancer research : an official  
36 journal of the American Association for Cancer Research*. 2017;23(17):5112-22.
- 37 177. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer  
38 metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. *The  
39 Journal of clinical investigation*. 2011;121(4):1298-312.
- 40 178. Gao D, Vela I, Sboner A, Iaquinata PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from  
41 patients with advanced prostate cancer. *Cell*. 2014;159(1):176-87.
- 42 179. Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, et al. The marrow niche controls  
43 the cancer stem cell phenotype of disseminated prostate cancer. *Oncotarget*. 2016;7(27):41217-32.
- 44 180. Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, et al. Increased expression of  
45 putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone  
46 metastasis progression. *The Prostate*. 2013;73(16):1738-46.
- 47 181. Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, et al. Metabolic  
48 Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic  
49 Therapy. *European urology focus*. 2017.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 182. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The  
4 evolutionary history of lethal metastatic prostate cancer. *Nature*. 2015;520(7547):353-7.  
5 183. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-  
6 cause and prostate cancer-specific mortality among men with diabetes. *Journal of clinical oncology :*  
7 *official journal of the American Society of Clinical Oncology*. 2013;31(25):3069-75.  
8 184. Pixberg CF, Raba K, Muller F, Behrens B, Honisch E, Niederacher D, et al. Analysis of DNA  
9 methylation in single circulating tumor cells. *Oncogene*. 2017;36(23):3223-31.  
10 185. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of  
11 circulating tumor cells from patients with localized and metastatic prostate cancer. *Science translational*  
12 *medicine*. 2010;2(25):25ra3.  
13 186. Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, et al. Vimentin and Ki67  
14 expression in circulating tumour cells derived from castrate-resistant prostate cancer. *BMC cancer*.  
15 2016;16:168.  
16 187. Decker AM, Jung Y, Cackowski FC, Yumoto K, Wang J, Taichman RS. Sympathetic Signaling  
17 Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow. *Molecular cancer*  
18 *research : MCR*. 2017;15(12):1644-55.  
19 188. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the  
20 genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in  
21 neoplastic and morphologically normal prostate tissue. *Nature genetics*. 2015;47(4):367-72.  
22 189. Lack J, Gillard M, Cam M, Paner GP, VanderWeele DJ. Circulating tumor cells capture disease  
23 evolution in advanced prostate cancer. *Journal of translational medicine*. 2017;15(1):44.  
24 190. Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, et al. Gene expression analysis of  
25 bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.  
26 *Journal of translational medicine*. 2016;14:72.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Figures and Tables

**Table 1.** Methods for detection and isolation of CSC populations.

**Table 2.** The features of prostate cancer stem cells (CSCs), circulating tumor cells (CTCs), disseminated tumor cells (DTCs) and metastasis initiating cells (MICs). **Figure 1.** Phenotypes of CSCs, DTCs, MICs and prostate tumor progression. Prostate cancer development is an evolutionary process that reflects an evolving of cancer stem cells. Luminal or basal cells in normal prostate can act as a cell of tumor origin after oncogenic transformation. The link between the tumor initiating cells, or tumor cell of origin and cancer stem cells (CSCs) that maintain tumor growth is not yet understood. Tumor metastases are driven by the evolved populations of CSCs at their worst. Some tumor cells with malignant potential enter the blood stream (circulating tumor cells, CTCs) and can be disseminated to the distant organs. Single prostate tumor cells that can be found in bone marrow and called disseminated tumor cells (DTCs). Single tumor cells disseminated to lymph nodes called isolated tumor cells (ITCs, not shown). A small subset of DTCs or ITCs becomes metastasis initiating cells (MICs). Metastatic spread and formation is a long-time process that might take a few years. Once formed, metastases can form secondary metastasis to distant organs. Prostate cancer progression is associated with development of substantial intra-tumor heterogeneity and genomic instability that can be induced by MYC activation, loss of PTEN and mutations in DNA repair genes including BRCA2, ATM and CHEK2. Acronyms: AR – androgen receptor; CK – cytokeratin; PSA – prostate specific antigen; ALDH – aldehyde dehydrogenase; ABCG2 , ATP binding cassette subfamily G member 2;  $\alpha 2\beta 1$  ,  $\alpha 2\beta 1$  Integrin; ERG1 , early growth response protein 1; PTEN , phosphatase and tensin homolog; EpCAM , epithelial cell adhesion molecule; HER2 , human epidermal growth

33

1  
2  
3 factor receptor 2; FGF , fibroblast growth factor; MAPK , mitogen-activated protein  
4  
5 kinase; PI3K , phosphatidylinositide 3-kinase; NF- $\kappa$ B , nuclear factor 'kappa-light-chain,  
6  
7 enhancer' of activated B-cells; TGF $\beta$  , transforming growth factor  $\beta$ ; EGFR , epidermal  
8  
9 growth factor receptor; CXCR4 , C-X-C chemokine receptor type 4; EZH2 , enhancer of  
10  
11 zeste homolog 2; BRCA2 , breast cancer type 2 susceptibility protein; ATM , ataxia  
12  
13 telangiectasia mutated; CHEK2 , checkpoint kinase 2.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1


**Table 1.** Methods for detection and isolation of CSC populations


| <b>Marker-based methods</b>  |   |                                 |   |  |  |
|--|---|---------------------------------|---|--|--|
| <b>Technique</b>   | <b>Method</b>   | <b>Markers</b>                  | <b>Ref</b>  | <b>Advantages</b>  | <b>Limitations</b>   |
| Staining cell surface targets / fluorescence detection of enzymatic activity | Fluorescence based cell sorting, IF microscopy, IHC   | CD44                            | (147)   | Analysis of the experimental (xenograft animal models) and clinical (patient(derived tissues, TMA) samples   | These markers are not specific for PCSC and express on other cells including normal tissues;<br><br>PCSC can be heterogeneous for the marker expression, and marker positive cells can be functionally heterogeneous (e.g. by their self(renewal properties) |
|  |   | CD133/CD44                      | (17, 147, 148)  |  |  |
|  |   | ALDH/CD44/ $\alpha$ 2 $\beta$ 1 | (27)  |  |  |
|  |   | CD166                           | (7)   |  |  |
| Gene reporter systems  | Fluorescence based cell sorting, fluorescence microscopy, <i>in vitro</i> and <i>in vivo</i> cell tracking          | PSA                             | (27)  | <i>In vitro</i> and <i>in vivo</i> tracking of CSC populations, <i>in vivo</i> CSC imaging, performance of phenotypic assays   |  |
|  |   | 26S proteasome activity         | (12)  |  |  |
|  |   | NANOG                           | (11, 16)  |  |  |
|  |   | CD44                            | (146)   |  |  |
| <b>Marker-free methods</b>   |   |                                 |   |  |  |
| <b>Technique</b>   | <b>Method</b>   | <b>Ref</b>                      | <b>Advantages</b>   | <b>Limitations</b>   |  |
| Sphere forming assay   | Cell cultivation under non(adherent conditions accompanied by FACS analysis to confirm CSC enrichment in spheres    | (150, 151)                      | Elucidation of molecular and physiological properties of CSCs;<br>CSC characteristics associated with treatment( resistance | This methods cannot be used to obtain a highly enriched CSC populations;<br><br>Sphere forming properties <i>in vitro</i> are not indicative for tumorigenicity <i>in vivo</i> |  |
| Therapy( induced CSC enrichment  | Cancer cell cultivation in the presence of chemotherapeutic drugs or repetitive cell exposure to ionizing radiation | (20, 152)                       |   |  |  |
| Side population  | Fluorescence sorting based on the Hoechst 33342 or Rhodamine 123 efflux by CSCs                                     | (6, 22)                         | Various samples can be analyzed e.g. cell lines, xenograft tumors and tumor specimens                                       | Hoechst 33342 and Rhodamine 123 are toxic; absence of the standard dye concentration; low specificity  |  |
| CSC isolation based on the cell sizes  | Microfluidic techniques, FACS   | (26, 153, 154)                  | Cells with different morphology, sizes and metabolic activities can be separated  | Low specificity  |  |

1

**Table 2.** The features of prostate cancer stem cells (CSC), circulating tumor cells (CTC), disseminated tumor cells (DTC) and metastasis initiating cells (MIC)

| Cells<br>Features            | Non-CSC<br>(tumor bulk)  | CSC   | CTC  | DTC   | MIC                   |
|------------------------------|--|---|--|---|-----------------------|
| Androgen receptor expression | AR <sup>+</sup> (luminal cells); AR <sup>low/-</sup> (basal cells) (64, 81, 155) | AR- (primary PC) or AR-/+ (CRPC) (3, 7, 156, 157)                   | AR- or AR+ (158-162)   | AR- or AR+ (163)  | AR- or AR+ (164, 165) |
| Anrogen dependence           | Primary PC: Yes<br>CRPC: No (70, 166)  | No (3, 27, 59, 157)   | Yes / No (158, 167, 168)                                       | Yes / No (165)  | Yes / No (165)        |
| PSA expression               | Yes (luminal cells) (3, 64)  | No (3) or low (169)   | PSA+ or PSA- (167, 168, 170)                                   | PSA+ or PSA- (171)  | No data               |
| Phenotype                    | Luminal or basal epithelial cells (166)  | Luminal or basal epithelial cells (3, 32, 65, 66, 73, 155, 172-174) | Epithelial or Mesenchymal (EMT) (114, 159, 162, 170, 175, 176) | Epithelial (171), Mesenchymal (EMT) (114), Hematopoietic (171, 177) | No data               |
| Tumorigenicity               | Upon de-differentiation (12, 169)  | Yes (3, 32, 65, 66, 73, 155, 172-174)                               | Probably (178)   | Probably (179, 180)   | Yes (181, 182)        |
| Metabolism                   | Primary PC: OXPHOS<br>CRPC: glycolysis (Warburg effect) (25, 37)                 | Glycolysis (88) or/and OXPHOS (74, 183)                             | No data  | No data   | No data               |
| Heterogeneity                | Yes (82)   | Yes (3, 32, 65, 66, 73, 155, 172-174)                               | Yes (159, 161, 162, 167, 170, 184)                             | Yes (163, 165, 171)   | Yes (181, 182)        |
| Cellular state               | Proliferative (166)  | Quiescent (3)   | Proliferative or quiescent (185, 186)                          | Dormant or quiescent (102, 187)                                     | No data               |
| Genetic evolving             | Yes (182, 188)   | Yes (188)   | Yes, reflection of tumor evolution (111, 112, 189)             | Yes (110) (90, 103-105)   | Yes (181, 182, 190)   |





410x147mm (96 x 96 DPI)